Liver support using extracorporeal devices and hepatocyte transplantation has received renewed interest for the management of acute and chronic liver failure. The aim of this study was to determine whether xenoge neic porcine hepatocytes could integrate into the liver parenchyma of cirrhotic Lewis rats when administered by an intrasplenic route. Cirrhosis was induced by carbon tetrachloride (CC1 4 ) inhalation and confirmed histologically. Freshly isolated porcine hepatocytes were infused directly into the splenic pulp at laparotomy over a 5-15-min interval. Using '"in-labeled hepatocytes, the degree of localization of porcine hepatocytes to the spleen and liver was found to be greater than 60% in both control and cirrhotic rats. Integration of porcine hepatocytes into the rat liver parenchyma was determined by immunohistochemical staining for porcine albumin in rat liver sections. Further confirmation was provided by in situ hybridization using a porcine-specific probe that binds to a distinct repetitive element (PRE) in porcine DNA. Evidence of inte grated porcine hepatocytes was seen for over 50 days in animals under cyclosporine immunosuppression. These data demonstrate the integration of xenogeneic porcine hepatocytes into the liver of the cirrhotic rat and their ability to produce porcine albumin for up to 50 days.
INTRODUCTION
Cirrhosis is a chronic liver disease characterized by progressive fibrosis of the liver with concomitant loss of liver function. Although the etiology of cirrhosis is variable, end-stage liver disease is predominantly treated by orthotopic liver transplantation to replace hepatocyte function or for complications of portal hypertension (7) . However, liver transplantation at the present time in the United States is inherently limited by the number of do nor organs (32) . Effective treatments for complications of cirrhosis such as transjugular intrahepatic porto-systemic shunts (TIPS) for variceal bleeding or ascites are available, but these are often associated with further loss of hepatocellular function and with further progression of encephalopathy (27) . Our ability to provide aggres sive treatment for complications of cirrhosis such as sur gical resection or chemoembolization for hepatoma is often compromised by the loss of hepatic function seen with these therapies. Any treatment that could even mar ginally improve hepatic function would result in a better tolerance to these new therapies.
Hepatocyte transplantation has received much inter est recently both in animal models and as a potential therapy for acute liver failure (3, 5, (9) (10) (11) (12) (13) 25, 30) . In ani mal models of acute liver disease, hepatocyte transplan tation has been associated with improvement in survival (17, 31, 33) . In chronic models of liver disease, hepato cyte transplantation has improved parameters such as porto-systemic encephalopathy (26) . These animal mod els have focused on syngeneic or allogeneic transplanta tion of hepatocytes (6, 12, 13, 16, 28, 33) . Syngeneic trans plantation is not an option for therapy in humans, and the same issues with lack of donor organs are likely to limit availability of human hepatocytes for allogeneic transplantation. The advent of xenogeneic hepatocellular transplantation, which has been successfully used to treat metabolic liver disease in the Watanabe hypercholesterolemic rabbit (9) , would suggest that xenotrans plantation might also be possible for chronic liver dis ease. Xenotransplantation of porcine cells into humans has recently been successfully performed for Parkin son's disease (4, 8) . In addition to their ability to perform many of the metabolic functions compromised in ad-vanced cirrhosis, the porcine hepatocytes are readily available.
Previously described studies of liver repopulation with hepatocytes have been performed predominantly in recipient animals with either metabolic disease or nor mal livers (15, 19, 25) . Integration of transplanted hepato cytes into a cirrhotic liver is more complex because of the increased perisinusoidal fibrosis and the presence of a porto-systemic collateral circulation. The increased he patic fibrosis could prevent transmigration of cells from the sinusoids into the liver parenchyma and prevent their integration into the liver plate. In addition, shunting via porto-systemic collaterals might lead to embolization of hepatocytes into the right heart and pulmonary circula tion.
In this study, we describe the integration of function ing xenogeneic porcine hepatocytes into the liver of cir rhotic rats without major embolization into other organs.
Medium-term survival of porcine hepatocytes was seen with immunosuppression. Although clinical and bio chemical improvement of liver function was not a mea sured end-point, this study demonstrates that liver repopulation with xenogeneic hepatocytes is possible in the cirrhotic rat.
MATERIALS AND METHODS

Animals
Forty adult male Lewis rats (Charles River Labora tories, Wilmington, MA) were used in these experi ments. All animals received humane care as outlined in
Guide for the Care and Use of Laboratory Animals
(NIH publication 86-23) and the studies were approved by the Laboratory Animal Sciences Committee of Bos ton University School of Medicine.
Induction of Cirrhosis
Induction of cirrhosis was achieved with a protocol modified from that initially described in detail by
McLean (18) . After a 10-day period of pretreatment with week, the animals were exposed to CCL vapor for 2 min and then the pump was turned off with the animals left in the chambers for an additional 2 min. The second
week the CCL vapor was administered for 4 min and 
Portal Pressure Measurements
Portal pressure was measured prior to and during the hepatocyte transplant in some animals and also at the time of sacrifice in other animals to evaluate long-term effect on portal pressure. Rats were anesthetized with an intramuscular injection of ketamine (100 mg/kg) and xylazine (10 mg/kg). Anesthesia was supplemented with further intramuscular injections as necessary. A midline laparotomy was performed and a 22-gauge angiocath was inserted into the portal vein and attached via arterial pressure tubing to a pressure transducer communicating with a Hewlett-Packard recorder.
Laboratory Tests
Serum was obtained from animals for bilirubin, ALT, and albumin prior to transplantation.
Histological
Staining of Liver Sections
Routine H&E, trichrome, scarlet acid fuschin, and an iline blue staining was performed on control and cir rhotic tissue after overnight fixation in Bouin's medium.
In Situ Hybridization
The formalin-fixed tissue was sectioned (4 pm) and
dried for 1 h. Sections were deparaffinized and treated for 30 min with 2.5 mg/ml proteinase K at 37°C and were then washed, dehydrated, and air dried. The hy bridization was done with a plasmid probe containing the porcine repetitive element that had been ligated to a T-tailed vector (20) . The probe was labeled with digoxygenin using a commercial kit (Boehringer Mannheihi).
The probe was added to the sections in 50% formamide and, following denaturation at 100°C for 10 min, the hybridization was performed overnight at 37°C. Devel 
Immunohistochemistry for Porcine Albumin
Liver tissue was fixed in formalin. Sections were pre pared and stained with hematoxylin and eosin (H&E).
Porcine albumin was identified using a specific goat anti-porcine albumin antibody. Detection was via a bio tinylated donkey anti-goat IgG (Biodesign) and biotin strepavidin peroxidase (Biogenex) using amino(ethyl)carbazole (AEC) as the chromagen. Negative controls were run on adjacent sections using no primary anti body.
"'in Labeling of Porcine Hepatocytes
Porcine hepatocytes were cultured in DMEM/Weymouth for 72 h prior to harvest. Cells were harvested with trypsin/EDTA and had a viability of 88% by trypan blue staining. Cells were resuspended in HBSS. Label ing was done essentially according to the procedure of Gupta (12) . "'In-oxime (2 mCi) was added to 7x 10 7 hepatocytes at room temperature. The cells were incu bated at room temperature for an additional 20 min prior to washing several times in HBSS. "'in-labeled hepato cytes (~2x 10 7 /0.5 ml) were injected into two control and two cirrhotic animals. Imaging was done every 30 s for the first 5-6 min, and then at 15 min and 2 h posttransplantation.
Following euthanasia the liver, spleen, heart, lung, and blood were removed. Samples were weighed and prepared for gamma counting in a Wallach 1470 Wizard gamma counter.
RESULTS
Transplantation of Hepatocytes
Control and cirrhotic animals were infused with por cine hepatocytes (1-4 x 10 7 ) into the splenic pulp. An exception was the injection of two cirrhotic animals with ing by both H&E and trichrome (Fig. 1) . The laboratory data for cirrhotic and control rats are given in Table 1 .
Cirrhotic rats all had elevated transaminase (ALT) lev els, hypoalbuminemia, and hyperbilirubinemia when com pared to the control group.
Portal Pressure Measurements
During infusion of hepatocytes into the spleen, ooz ing was noted around the portal vein catheter. Portal hy pertension with an elevation in portal pressure above 10 mmHg was noted at baseline in all cirrhotic rats in which it was measured (n = 6, Table 1 ). Portal pressure was not measured in all cirrhotic animals because it was felt that significant loss of cells could occur from oozing around the portal vein catheter. A mean 3.1 mmHg rise in portal pressure was seen during the hepatocyte infu sion into the cirrhotic rats, whereas a lesser increase was seen after infusion into control rats without cirrhosis or portal hypertension (Table 1) . At the time of sacrifice, portal pressure was measured again and had fallen to the baseline levels ( Table 1) .
Localization of Labeled Porcine Hepatocytes
Using "'in-labeled porcine hepatocytes the biodistribution of the infused cells was determined using scintig raphy. Two control and two cirrhotic rats were infused with 2 x 10 7 labeled cells. The animals were imaged at 30-s intervals. The early scans showed the rapid migra tion of the hepatocytes from the spleen to the liver (Fig.   2 ). There was no significant difference in the percentage of cells localized to the liver between the control and cirrhotic animals ( Table 2) . At 2 h all animals had 29.4 ± 5.5% of the cells residing in the liver. Over 60% of all labeled cells were either in the spleen or liver of the rats 2 h after infusion. Approximately 30% of the la beled cells were found in the circulation; 1% or less of the cells were found in the lungs in 3 out of 4 animals.
However, in one of the cirrhotic animals 5% of the total radioactivity was present in the lung parenchyma.
Immunohistochemistry and In Situ Hybridization
Animals were sacrificed at early time points of 0, 1, 3, and 5 days posttransplantation to determine if any major differences in cell dispersion occurred between the control (n = 5) and cirrhotic (« = 12) animals. Imme diately following infusion much of the portal vasculature was completely filled with hepatocytes, which stained strongly positive for porcine albumin (data not shown).
By 1 day posttransplant only small clusters of the cells
were localized to the portal vasculature and sinusoids (data not shown) and by day 5 without immunosuppres sion no cells were seen in the sinusoids or portal vessels.
Because there was no cell survival in either control rats or cirrhotic rats after day 5 without immunosuppression, all the longer term studies were done on cyclosporine and the majority of the data given below is for cirrhotic rats on cyclosporine.
Examination of sections of heart and lungs showed no evidence for porcine hepatocytes by H&E or porcine albumin immunostaining at day 5. H&E did not demon strate any porcine hepatocytes in the spleen but rare PRE-positive cells were seen in the spleen at day 7 in animals on cyclosporine. At day 50, no extrahepatic por cine cells were found.
In the cirrhotic rats, immunohistochemistry for por cine albumin was performed at days 7, 50, and 57 after transplantation in rats receiving cyclosporine (n = 8). In the cirrhotic rats receiving cyclosporine, porcine albu min-positive cells were seen in clusters within the he patic plates in three of four animals at day 7 (Fig. 3) .
However, by day 50 clusters were no longer visible and only focal rare hepatocytes were seen positive for por cine albumin in these same rats.
Using the PRE probe for in situ hybridization, the presence of porcine hepatocytes was confirmed in the same cirrhotic animals that were positive for porcine al bumin by immunohistochemistry (Fig. 4 ). This con firmed the specificity of the albumin stain for integrated porcine hepatocytes. In animals on immunosuppression and kept alive for 50 days or more, only two of four had PRE-positive cells (Fig. 4C ). Cirrhotic rats that did not receive immunosuppression had no detectable porcine hepatocytes by PRE in situ hybridization after day 5. tension was achieved despite the marked scarring and fibrosis in the recipient liver.
DISCUSSION
Although our study demonstrated successful integra tion of porcine hepatocytes in the cirrhotic rat liver, we did not measure any parameters indicative of improve ment in clinical outcome. We transplanted between 1% and 2% of the total mass of hepatocytes in a rat liver and found by examination of multiple liver sections that although initial 7-day integration was estimated to be between 5% and 10% of transplanted hepatocytes, that by day 50 there was no more than 1% of the transplanted hepatocytes integrated in the host liver. Because this was a xenotransplant, porcine-specific markers were used for unequivocal detection of porcine albumin and DNA. In tegration was initially (day 7) in clusters of cells as has been seen in other syngeneic models of hepatocyte transplantation in rats. However, these clusters could represent either the initial cells that were transplanted or a few isolated cells that have undergone several divi sions during integration. Interestingly, by day 50 the number of viable porcine cells had reduced dramatically to the occasional focal positive cell. This may represent porcine cell rejection with time and it is quite clear that immunosuppression is necessary for successful xeno transplantation in this model. Gupta et al. (11) , using synthetic fluorescent bile acids, have previously demonstrated bile salt secretion in transplanted syngeneic rat hepatocytes, suggesting in tact bile acid transport mechanism in the transplanted hepatocytes. In order to adequately show improvement in hepatic function, survival studies in larger numbers of xenotransplanted cirrhotic rats would be necessary. In vitro porcine cells have similar synthetic, metabolic, and detoxification properties as human hepatocytes (22, 34) .
The question of what percentage of transplanted hepato cyte mass is necessary will have to be addressed before clinical improvements in long-term function and sur vival can be identified.
In this study, only one transplantation procedure was performed per animal and limited numbers of cells were perfused. The rapid onset of cardiopulmonary failure seen in cirrhotic animals given 10% (1 x 10 8 cells) of the liver mass suggests that there is an upper limit of safety above which shunting into the pulmonary circula tion is a major problem. Similar findings in syngeneic transplantation of rat hepatocytes were reported by Gupta (12, 13) , who also demonstrated a somewhat dif ferent biodistribution of hepatocytes by '"in labeling. In our study, the "'in-labeled hepatocytes had an even dis tribution at 2 h in liver and spleen; this is a little unusual because we would have expected more rapid transloca tion from the spleen to the liver, as was noted by Gupta (12) . The slower rate of translocation may be due to the injection technique or perhaps due to the our use of por cine cells compared to the rat hepatocytes in other stud ies. However, multiple infusions of small numbers of hepatocytes to achieve an integrated liver mass of trans-planted hepatocytes of 5% could be clinically possible assuming that enough cells were available and that a minimally invasive vascular approach was employed. Other alternatives to increase the hepatocyte mass in clude using hepatocyte stem cells or fetal cells that may be better able to proliferate when stimulated by hepato cyte growth factors. Alternatively, methods could be de veloped to improve the ability of hepatocytes to migrate across the sinusoid and integrate in the liver. Gupta and colleagues (23) have shown that the use of sinusoidal vasodilators such as the a-adrenergic blocker phentolamine can allow for an increased number of hepatocytes to be infused into the portal vein and perhaps lead to integration of more cells. However, it is possible that excess administration of hepatocytes results in microcirculatory ischemic injury to the liver (24) . Future studies will therefore focus on better defining both the percent age of liver mass and the number of transplantation pro cedures that are necessary to ensure adequate integration of enough hepatocytes to produce an improvement in clinical outcomes.
Although we have shown integration of cells into the cirrhotic liver, the optimal site of transplantation is again controversial (14). Both spleen and liver have been con sidered as sites for infusion of hepatocytes. Liver repopulation has some advantages because in this environ ment both integration and function of transplanted
hepatocytes are likely to be optimal. However, in the cirrhotic patient there may be ongoing hepatic inflam mation with release of local cytokines that could lead to destruction of the transplanted cells. Alternatively, local production of hepatocyte growth factors and stimulatory cytokines may increase the proliferation of hepatocytes in the liver more than in the spleen. The degrees of fi brosis and portal hypertension are also critical in deter mining the choice of site for transplantation, because the fibrosis may retard the ability of cells to proliferate, and the portal hypertension may deprive the transplanted cells of essential oxygenation and nutrients. In synge neic transplantation, studies using BrdU labeling have suggested that transplanted hepatocytes proliferate. As few as one to two cell divisions would make a large difference in the number of hepatocytes that need to in tegrate within the host liver.
Because the optimal site for transplantation in the cir rhotic patient is unclear, studies in humans have com bined attempts at liver repopulation with splenic trans plantation of hepatocytes (2,20,30). Even though the number of cases reported so far is limited, moderate suc cess has been achieved with this approach using human hepatocytes and cyclosporine immunosuppression. The rationale behind the use of xenotransplantation is that the supply of donor human livers is limited and the tech nology to culture sufficient quantities of human hepato cytes is not available. However, several recent advances indicate that human hepatocytes can be used clinically for liver support in fulminant liver failure as well as chronic liver failure (29,30). Bilir and colleagues (2) have demonstrated improvement of encephalopathy in cirrhotic patients with intrasplenic human hepatocyte transplantation. Our focus on xenotransplantation with porcine hepatocytes has the potential to markedly in crease the availability of this procedure for patients with chronic liver disease and liver failure. For long-term efficacy of this procedure in humans, the problem of xenogeneic rejection will have to be overcome. One ad vantage inherent to isolated cells compared to intact vas cularized organs is that the barriers to xenotransplanta tion are lower.
In conclusion, we have successfully demonstrated the integration of porcine xenogeneic hepatocytes into the cirrhotic rodent liver with adequate short-term 7-day survival and function to suggest that future studies be directed to determine the optimal site, number, and type of xenogeneic hepatocyte necessary for in vivo liver support.
